Latest Breaking News On - Dose escalation data - Page 1 : comparemela.com

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic.

United statesNorth carolinaConor richardsonShattuck labs incInitial clinical trial dataDose escalation dataInvestor relationsShattuck labsAgonist redirected checkpointMedia contact

Shattuck Labs to Host Investor Call and Webcast to Share

Shattuck Labs to Host Investor Call and Webcast to Share
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesConor richardsonShattuck labs incInitial clinical trial dataDose escalation dataInvestor relationsShattuck labsAgonist redirected checkpointMedia contact

Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results

Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients.

United kingdomAlexandra balcomJames porterPiper sandlerExchange commissionPrnewswire nuvalent incNuvalent incCompany quarterly report on formPreliminary phaseChief executive officerChief financial officerDose escalation dataDemonstrates proof of conceptBest in class clinical profilePatient derived models continuesSupport best in class preclinical profile

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaIrina kofflerPaul mcbarronDysregulated cdksExchange commissionCyclacel pharmaceuticals incLifesci advisorsDose escalation dataSolid tumorsMolecular targetsCancer therapeuticsMulti center studyAdvanced solid tumorsTargeted agentsCyclin dependent kinasesCyclacel pharmaceuticals

Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results

/PRNewswire/ Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically.

United kingdomJames porterAdditional development candidatesNuvalent incCompany annual report on formPrnewswire nuvalent incExchange commissionChief executive officerPipeline achievementsAnticipated near termDose escalation dataSecond halfEnrollment ongoingData presentedLung cancer annual meetingLung cancer